Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Evaluating the Bispecific CD3xCD20 Antibody GLOfitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) in Patients With RIchter Syndrome as Frontline therapY. A FILO Study

NCT06186648 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT06186648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06186648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Evaluating the Bispecific CD3xCD20 Antibody GLOfitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) in Patients With RIchter Syndrome as Frontline therapY. A FILO Study
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Recruiting
Start date
March 21, 2024
Completion date
September 4, 2029
Enrollment
40 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

richter syndrome